The genetic spectrum of familial hypercholesterolemia in the central south region of China

Atherosclerosis

Volumn 258, Issue , 2017, Pages 84-88

  Xiang, Rong ^a,b   Fan, Liang Liang ^a   Lin, Min Jie ^b   Li, Jing Jing ^a   Shi, Xiang Yu ^b   Jin, Jie Yuan ^a   Liu, Yu Xing ^a   Chen, Ya Qin ^b   Xia, Kun ^a   Zhao, Shui Ping ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

APOB; Familial hypercholesterolemia; LDLR; Mutation spectrum; PCSK9

Indexed keywords

APOLIPOPROTEIN B; GENOMIC DNA; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE 9; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; LDLR PROTEIN, HUMAN; LIPID; PCSK9 PROTEIN, HUMAN;

ADULT; ARTICLE; CHINA; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE FREQUENCY; GENE MUTATION; HOMOZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; XANTHOMA; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; DNA MUTATIONAL ANALYSIS; EPIDEMIOLOGY; ETHNOLOGY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MUTATION; PHENOTYPE; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; APOLIPOPROTEIN B-100; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; CHINA; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MUTATION; PHENOTYPE; PROPROTEIN CONVERTASE 9; RECEPTORS, LDL; RISK FACTORS; YOUNG ADULT;

EID: 85013104664     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2017.02.007     Document Type: Article

References (27)

1. [1] Rana, J.S., Liu, J.Y., Moffet, H.H., et al. Metabolic dyslipidemia and risk of coronary heart disease in 28,318 adults with diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am. J. Cardiol. 116 (2015), 1700–1704.
2. [2] Yusuf, S., Hawken, S., Ounpuu, S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004), 937–952.
3. [3] European Association for Cardiovascular, P, Rehabilitation, Reiner, Z, et al.ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of Cardiology (ESC) and the European atherosclerosis society (EAS). Eur. heart J. 32 (2011), 1769–1818.
4. [4] Task Force for the management of dyslipidaemias of the European Society of, C, the European Atherosclerosis, S, Catapano, AL, et al.ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of Cardiology (ESC) and the European atherosclerosis society (EAS). Atherosclerosis 217:Suppl 1 (2011), S1–S44.
5. [5] Hovingh, G.K., Davidson, M.H., Kastelein, J.J., et al. Diagnosis and treatment of familial hypercholesterolaemia. Eur. heart J. 34 (2013), 962–971.
6. [6] Jiang, L., Sun, L.Y., Pan, X.D., et al. Characterization of the unique Chinese W483X mutation in the low-density lipoprotein-receptor gene in young patients with homozygous familial hypercholesterolemia. J. Clin. Lipidol. 10 (2016), 538–546 e535.
7. [7] Fan, L.L., Lin, M.J., Chen, Y.Q., et al. Novel mutations of low-density lipoprotein receptor gene in China patients with familial hypercholesterolemia. Appl. Biochem. Biotechnol. 176 (2015), 101–109.
8. [8] Futema, M., Plagnol, V., Li, K., et al. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J. Med. Genet. 51 (2014), 537–544.
9. [9] Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. heart J. 34 (2013), 3478–3490a.
10. [10] Xiang, R., Fan, L.L., Huang, H., et al. A novel mutation of GATA4 (K319E) is responsible for familial atrial septal defect and pulmonary valve stenosis. Gene 534 (2014), 320–323.
11. [11] Sunyaev, S., Ramensky, V., Bork, P., Towards a structural basis of human non-synonymous single nucleotide polymorphisms. Trends Genet. TIG 16 (2000), 198–200.
12. [12] Ng, P.C., Henikoff, S., SIFT: predicting amino acid changes that affect protein function. Nucleic acids Res. 31 (2003), 3812–3814.
13. [13] Schwarz, J.M., Rodelsperger, C., Schuelke, M., et al. MutationTaster evaluates disease-causing potential of sequence alterations. Nat. methods 7 (2010), 575–576.
14. [14] Mollaki, V., Progias, P., Drogari, E., Familial Hypercholesterolemia in Greek children and their families: genotype-to-phenotype correlations and a reconsideration of LDLR mutation spectrum. Atherosclerosis 237 (2014), 798–804.
15. [15] Sharifi, M., Walus-Miarka, M., Idzior-Walus, B., et al. The genetic spectrum of familial hypercholesterolemia in south-eastern Poland. Metabolism Clin. Exp. 65 (2016), 48–53.
16. [16] Jiang, L., Sun, L.Y., Dai, Y.F., et al. The distribution and characteristics of LDL receptor mutations in China: a systematic review. Sci. Rep., 5, 2015, 17272.
17. [17] Nanchen, D., Gencer, B., Muller, O., et al. Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes. Circulation 134 (2016), 698–709.
18. [18] Schofield, J., Kwok, S., France, M., et al. Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey. Atherosclerosis 252 (2016), 161–165.
19. [19] Pimstone, S.N., Sun, X.M., du Souich, C., et al. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arteriosclerosis, thrombosis, Vasc. Biol. 18 (1998), 309–315.
20. [20] Gent, J., Braakman, I., Low-density lipoprotein receptor structure and folding. Cell. Mol. life Sci. CMLS 61 (2004), 2461–2470.
21. [21] Fernandez-Higuero, J.A., Etxebarria, A., Benito-Vicente, A., et al. Structural analysis of APOB variants, p. (Arg3527Gln), p. (Arg1164Thr) and p. (Gln4494del), causing Familial Hypercholesterolaemia provides novel insights into variant pathogenicity. Sci. Rep., 5, 2015, 18184.
22. [22] Medeiros, A.M., Alves, A.C., Francisco, V., et al. Update of the portuguese familial hypercholesterolaemia study. Atherosclerosis 212 (2010), 553–558.
23. [23] Hopkins, P.N., Defesche, J., Fouchier, S.W., et al. Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody, circulation. Cardiovasc. Genet. 8 (2015), 823–831.
24. [24] Abifadel, M., Guerin, M., Benjannet, S., et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis 223 (2012), 394–400.
25. [25] Fahed, A.C., Khalaf, R., Salloum, R., et al. Variable expressivity and co-occurrence of LDLR and LDLRAP1 mutations in familial hypercholesterolemia: failure of the dominant and recessive dichotomy. Mol. Genet. genomic Med. 4 (2016), 283–291.
26. [26] Lange, L.A., Hu, Y., Zhang, H., et al. Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. Am. J. Hum. Genet. 94 (2014), 233–245.
27. [27] Tosi, I., Toledo-Leiva, P., Neuwirth, C., et al. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith hospital lipid clinic. Atherosclerosis 194 (2007), 102–111.